Full-Time

Sales Operations Manager

Field Data & Reporting, Rep Alerts/Suggestions Program Analyst

Posted on 12/1/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Sales & Account Management
Required Skills
Machine Learning
Data Analysis
Requirements
  • Master’s degree & 8+ years of experience in Bio/Pharmaceutical Analytics, Data, and Reporting
  • Bachelor’s degree & 10+ years of experience in Bio/Pharmaceutical Analytics, Data, and Reporting
Responsibilities
  • Program Management: Support the ongoing management and execution of Amgen’s Rep Alerts/Suggestions program
  • Lead the cross-functional team to design, implement, and operationalize the Rep Alerts/Suggestions capability
  • Oversee cadence and delivery of Rep Alerts/Suggestions to US field sales teams, ensuring accuracy, timeliness, and business relevance
  • Evaluate and implement new approaches (AI/ML, automation, personalization) to improve the quality of Rep Alerts/Suggestions
  • Drive continuous improvements in the end-to-end process, from data ingestion to field delivery
  • Benchmark Amgen’s capabilities against industry best practices
  • Field Enablement & Adoption: Partner with Field Effectiveness and Sales Leadership to develop communication and training materials to ensure field representatives understand and adopt Rep Alerts/Suggestions effectively
  • Gather feedback from field users to continuously improve relevance, usability, and impact of Rep Alerts/Suggestions
  • Governance & Compliance: Maintain documentation of business rules, model assumptions, and decision logic underlying Rep Alerts/Suggestions
  • Ensure compliance with Amgen’s compliance, legal, and data privacy requirements
  • Develop and maintain the standards for the Rep Alerts/Suggestions capability
  • Measuring Value & Business Impact: Define and execute methodologies to measure the business value of Rep Alerts/Suggestions for a brand
  • Quantify impact through KPIs such as field adoption, engagement effectiveness, sales impact, etc.
  • Provide insights and recommendations to Sales Leadership on maximizing the impact of the Rep Alerts/Suggestions
  • Cross-Functional Alignment, Collaboration, & RACI Ownership: Develop, maintain, and enforce the RACI framework and the capability playbook to drive clarity of roles and responsibilities across functions
  • Act as a bridge between Analytics, Data Management, Decision Sciences, Field Excellence, Technology, and Business Stakeholders to ensure seamless delivery of Rep Alerts/Suggestions
  • Use the RACI to proactively identify ownership gaps, streamline decision-making, and support efficient and scalable planning and execution
  • Align business requirements with technical solutions, balancing scalability, performance, supportability, and user experience
Desired Qualifications
  • Technical Expertise: Experience with data-drive insights delivery capabilities
  • Experience with overseeing complex systems, integrations, and processes and being able to understand how a capability works end-to-end
  • Strong problem solving skills, with the ability to diagnose issues, identify root causes, and mobilize teams to resolve problems within a complex environment
  • Experience with industry standard field-facing tools such as CRM (e.g. Veeva) and Alignment and Roster management systems/data
  • Program Management and Governance: Proven ability to establish and manage structured programs in a complex, cross-functional environment
  • Experience building and maintaining RACI frameworks to ensure clarity, alignment, and accountability across stakeholders
  • Strong track record of managing program roadmaps, governance processes, and cross-team dependencies
  • Experience driving change management and securing field adoption of new capabilities
  • Measuring Business Impact: Demonstrated ability to measure and communicate the value of analytics/insight programs at a brand or enterprise level
  • Experience defining and tracking KPIs such as adoption rates, engagement effectiveness, sales impact, and ROI
  • Ability to make data-driven recommendations on how to maximize the impact of a capability
  • Ability to partner with business stakeholders to ensure programs and capabilities meet business objectives and needs
  • Collaboration & Communication: Strong stakeholder management skills, with the ability to partner effectively across Analytics, Data Management, Decision Sciences, Field Excellence, Technology, and Business Stakeholders
  • Excellent written and verbal communication skills, with the ability to translate complex technical ideas into clear, business terms
  • Proven ability to influence leaders and align diverse teams around program goals and objectives
  • Industry & Domain Knowledge: Experience working with commercial data sets in Bio/Pharmaceutical industry (e.g. sales, CRM, Patient Hub data, Field Force Effectiveness metrics)
  • Strong understanding of Bio/Pharmaceutical field force effectiveness, commercial operations processes, and customer engagement models
  • Understanding of compliance and privacy considerations in delivering field-facing insights
  • Leadership & Other Qualifications: Highly organized, detail-oriented, and able to manage competing priorities in a fast-paced environment
  • Strong problem-solving and critical-thinking skills with a proactive mindset
  • Demonstrated ability to foster a culture of continuous improvement and innovation
  • Demonstrated ability to align cross-functional teams to a common goal and shared sense of accountability

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE